Biomarkers

Diagnostic biomarkers on the horizon in Alzheimer’s disease

Trends in the use of surrogate biomarkers during clinical trials

Streamlining dementia diagnosis with digital biomarkers

Digital markers detect changes in neurocognitive performance in those with vs without hearing loss

The reality of implementing an Alzheimer’s disease ‘blood test’ in clinical practice

Research needs: determining reliability and robustness of plasma markers in Alzheimer’s disease

Blood biomarkers for the differential diagnosis of Alzheimer’s disease in clinical practice

Decreased kidney function associated with increased plasma p-tau levels

Validating blood-based biomarker assays for use in Alzheimer’s disease clinical care

Relationship between amyloid and tau modulated by astrocyte reactivity

Comparing the performance of blood-based amyloid and tau assays

Sex and gender biases in AI

BBB disruption impacts amyloid biomarker performance

Why does tau-PET not detect the earliest stages of Alzheimer’s disease?

Latest knowledge on plasma p-tau in Alzheimer’s disease

Alzheimer’s disease subtypes identified based on blood proteomics